Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · IEX Real-Time Price · USD
3.060
-0.170 (-5.26%)
At close: Jul 19, 2024, 4:00 PM
3.020
-0.040 (-1.31%)
Pre-market: Jul 22, 2024, 8:00 AM EDT
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$250,006
Profits / Employee
-$329,870
Market Cap
296.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AngioDynamics | 815 |
Adaptimmune Therapeutics | 449 |
SOPHiA GENETICS | 430 |
Alimera Sciences | 159 |
Enanta Pharmaceuticals | 145 |
Atea Pharmaceuticals | 75 |
Orchestra BioMed Holdings | 56 |
PSTX News
- 20 days ago - Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum - PRNewsWire
- 6 weeks ago - Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - PRNewsWire
- 2 months ago - Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PRNewsWire
- 2 months ago - Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting - PRNewsWire
- 2 months ago - Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - PRNewsWire
- 3 months ago - Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting - PRNewsWire
- 3 months ago - Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus - PRNewsWire
- 3 months ago - Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma - PRNewsWire